F. Hoffmann-La Roche Announces Half Year Results 2026
Filed with TSE · · 1 page · English
Chugai Pharmaceutical Co., Ltd. on 6ix
In the deck
Earlier from Chugai Pharmaceutical
- Chugai Files New Drug Application in Japan for Sparsentan for the Treatment of IgA Nephropathy
- Chugai Receives The Imperial Invention Prize, the Highest Honor of the FY2026 National Commendation for Invention, Recycling Antibody Technology Recognized for its Contribution to Pharmaceutical Research
- Chugai Pharmaceutical: Alecensa Receives the World-First Tumor-Agnostic Approval for ALK Fusion Gene-Positive Solid Tumors Across Adult and Pediatric Patients
- Chugai Pharmaceutical Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Alecensa for ALK Fusion Gene-Positive Solid Tumors
- Q1 Results (Jan-Mar 2026)
Later from Chugai Pharmaceutical
- CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)
- Chugai Announces 2026 2nd Quarter Results
- Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
- Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
- Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA
Follow Chugai Pharmaceutical into a list and get an email when it puts out news.
Follow Chugai Pharmaceutical